Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study

Frisullo, G., Calabrese, M., Tortorella, C., Paolicelli, D., Ragonese, P., Annovazzi, P., Radaelli, M., Malucchi, S., Gallo, A., Tomassini, Valentina ORCID: https://orcid.org/0000-0002-7368-6280, Nociti, V., D'Onghia, M., Lo Re, V., Rodegher, M., Solaro, C. and Gasperini, C. 2014. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Multiple Sclerosis Journal 20 (9) , p. 1265. 10.1177/1352458514521311

Full text not available from this repository.

Abstract

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing–remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Sage
ISSN:	1352-4585
Last Modified:	28 Oct 2022 09:38
URI:	https://orca.cardiff.ac.uk/id/eprint/75184

Citation Data

Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item